Srinivasan Ramanathan

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. doi request reprint Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Clin Pharmacokinet 50:229-44. 2011
  2. doi request reprint Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents
    Srinivasan Ramanathan
    Clinical Research, Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 64:45-50. 2013
  3. doi request reprint Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 53:209-14. 2010
  4. ncbi request reprint Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 45:274-9. 2007
  5. ncbi request reprint Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects
    Srinivasan Ramanathan
    Gilead Sciences Inc, Foster City, CA 94404, USA
    J Clin Pharmacol 46:559-66. 2006
  6. ncbi request reprint Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
    Srinivasan Ramanathan
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:160-6. 2007
  7. ncbi request reprint Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 13:1011-7. 2008
  8. ncbi request reprint Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin
    Joseph M Custodio
    Gilead Sciences, Inc, Foster City, CA, USA
    J Clin Pharmacol 54:649-56. 2014
  9. pmc Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment
    Joseph M Custodio
    Gilead Sciences, Inc, Foster City, California, USA
    Antimicrob Agents Chemother 58:2564-9. 2014
  10. doi request reprint Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Calvin Cohen
    Gilead Sciences Inc, Foster City, California, USA
    AIDS 25:F7-12. 2011

Collaborators

Detail Information

Publications12

  1. doi request reprint Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Clin Pharmacokinet 50:229-44. 2011
    ....
  2. doi request reprint Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents
    Srinivasan Ramanathan
    Clinical Research, Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 64:45-50. 2013
    ..The effects of various representative acid-reducing agents on the pharmacokinetics (PK) of boosted elvitegravir were evaluated by 1-way interaction in 4 studies...
  3. doi request reprint Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 53:209-14. 2010
    ..The pharmacokinetic (PK) interaction between ritonavir-boosted elvitegravir (elvitegravir/r) and maraviroc was evaluated...
  4. ncbi request reprint Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 45:274-9. 2007
    ..To evaluate the potential for clinically relevant drug-drug interaction between emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and the ritonavir-boosted HIV integrase inhibitor GS-9137 (GS-9137/r)...
  5. ncbi request reprint Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects
    Srinivasan Ramanathan
    Gilead Sciences Inc, Foster City, CA 94404, USA
    J Clin Pharmacol 46:559-66. 2006
    ..These results indicate that coadministration of tenofovir disoproxil fumarate and ribavirin does not result in substantial changes to their individual pharmacokinetic profiles...
  6. ncbi request reprint Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
    Srinivasan Ramanathan
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:160-6. 2007
    ....
  7. ncbi request reprint Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 13:1011-7. 2008
    ....
  8. ncbi request reprint Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin
    Joseph M Custodio
    Gilead Sciences, Inc, Foster City, CA, USA
    J Clin Pharmacol 54:649-56. 2014
    ..Elvitegravir and cobicistat pharmacokinetics were comparable to historical data. Rosuvastatin may be coadministered with EVG/COBI/FTC/TDF without dose adjustment. ..
  9. pmc Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment
    Joseph M Custodio
    Gilead Sciences, Inc, Foster City, California, USA
    Antimicrob Agents Chemother 58:2564-9. 2014
    ..No PK or safety data are available for EVG or COBI in subjects with severe hepatic impairment. ..
  10. doi request reprint Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Calvin Cohen
    Gilead Sciences Inc, Foster City, California, USA
    AIDS 25:F7-12. 2011
    ..To assess the safety and efficacy of two, single-tablet regimens for the initial treatment of HIV infection...
  11. doi request reprint Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection
    Joseph M Custodio
    Gilead Sciences, Inc, Foster City, CA, 94404, USA
    J Clin Pharmacol 54:378-85. 2014
    ..9 and 79.2, respectively), rilpivirine Cmax was narrowly above (129). Rilpivirine/emtricitabine/tenofovir disoproxil fumarate should be administered with food, which can be a standard or light meal. ..
  12. ncbi request reprint Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration
    Brian P Kearney
    Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    J Clin Pharmacol 45:935-40. 2005
    ..These results demonstrate that coadministration of tenofovir disoproxil fumarate and adefovir dipivoxil does not result in substantial changes to their individual pharmacokinetic profiles...